Tactile Systems Technology (TCMD) Peer Comparison

$23.16

$0.05 (0.22%)

As on 28-Aug-2026 16:00EDT

Market cap

$540 Mln

Revenue (TTM)

$350 Mln

P/E Ratio

21.9

P/B Ratio

2.4

Div. Yield

0 %

Edit

	Tactile Systems Technology (TCMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Market cap ($ Mln)	540	12,753	10,906	10,222	9,762
Revenue ($ Mln)	350	1,505	613	785	2,589
Net Profit ($ Mln)	24.87	160.59	-188.05	41.54	222.40
Net Margin (%)	7.10	10.67	-30.68	5.29	8.59
RoE (%)	11.23	10.86	-28.10	1.97	3.04
Price to Earnings	21.85	79.35	--	251.57	44.47
Price-To-Book	2.37	8.41	16.38	4.84	1.26

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Tactile Systems Technology (TCMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Operating Revenue	350.31	1,504.87	612.84	785.10	2,589.30
Cost of Revenue	90.28	483.98	127.96	384.30	1,245.50
Gross Profit	247.70	942.44	393.22	347.62	1,343.60
Operating Expenses	225.01	833.56	565.37	335.50	1,108.90
Operating Profit (EBIT)	35.03	187.34	-80.49	65.30	235.00
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	37.36	203.83	-192.83	52.15	350.40
Provision for Tax	12.49	43.24	-4.79	10.61	128.00
Profit after Tax (Net Income)	24.87	160.59	-188.05	41.54	222.40
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Tactile Systems Technology (TCMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Shareholder's Funds	223.84	1,530.77	682.49	2,112.03	7,173.90
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	17.58	210.18	135.71	705.49	2,116.80
Current Liabilities	38.25	233.78	102.33	132.66	961.30
Total Liabilities	273.94	1,826.52	893.49	2,949.70	10,576.50

Assets ($ Mln)

	Tactile Systems Technology (TCMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Non-Current Assets	122.07	630.60	404.74	1,749.63	7,231.50
Current Assets	157.60	1,344.12	515.78	1,200.55	3,020.50
Total Assets	273.94	1,826.52	893.49	2,949.70	10,576.50
Total Debt*	14.36	212.71	102.84	690.94	1,203.70
Net Current Assets	0.00	1,110.35	413.45	1,067.90	2,059.20

Cashflow ($ Mln)

	Tactile Systems Technology (TCMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Cash From Operating Activities	42.81	238.66	-46.34	117.42	532.20
Cash Flow from Investing Activities	-2.54	-404.59	-77.61	-298.47	-189.70
Cash from Financing Activities	-51.20	26.53	11.89	-15.21	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Tactile Systems Technology (TCMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
ROCE (%)	7.69	11.76	-22.53	1.79	8.98
ROE (%)	11.23	10.86	-28.10	1.97	3.04
ROA (%)	6.62	7.95	-18.00	1.36	2.02
EBIT Margin (%)	10.68	13.63	-30.58	9.87	-5.99
Net Margin (%)	7.10	10.67	-30.68	5.29	8.59
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Tactile Systems Technology (TCMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Revenue Growth (%)	17.22	17.55	41.55	16.49	1.37
EBIT Growth (%)	53.17	17.49	-116.42	920.91	-131.06
Net Profit Growth (%)	64.52	8.72	-102.66	400.42	-30.32
EPS Growth (%)	74.38	8.12	-96.88	394.30	-29.66
Book Value Growth (%)	15.72	17.33	-12.65	2.16	2.19

Valuation Ratios

	Tactile Systems Technology (TCMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Price / Earnings	35.01	68.93	-34.59	189.42	--
Price / Book Value	3.05	8.58	9.90	4.40	--
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	14.99	53.25	-43.50	55.90	--
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Tactile Systems Technology (TCMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debt to Equity	0.00	0.00	0.00	0.26	0.11
Short term debt to equity ratio	0.01	0.01	0.00	0.01	0.06
Current Ratio	4.12	5.75	5.04	9.05	3.14
Quick Ratio	3.68	3.86	4.46	7.64	2.33
Interest Coverage	149.84	157.91	-38.31	3.36	8.18

Operating Efficiency Ratios

	Tactile Systems Technology (TCMD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debtors to sales (%)	12.31	12.65	22.67	20.09	17.06
Asset Turnover	0.93	0.74	0.59	0.26	0.24
Receivable days	49.22	46.54	60.95	72.41	65.39
Inventory Days	72.97	331.92	193.84	146.53	221.09
Payable days	23.70	26.16	60.19	29.05	37.02
Cash Conversion Cycle	98.49	352.30	194.60	189.88	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly